The global breast lesion localization market is projected to reach USD 0.4 billion by 2028 from USD 0.3 billion in 2023, at a CAGR of 6.9% during the forecast period. Growth in this market can primarily be attributed to the increasing technological advancements in breast lesion localization equipment and increasing number of breast biopsies.
The prominent players in the anesthesia equipment market include Hologic, Inc. (US), Becton, Dickinson and Company (US), Merit Medical Systems (US), Leica Biosystems Nussloch GmbH (US), Argon Medical Devices (US). Players in the global anesthesia equipment market have employed various strategies to expand their global footprints and increase their market shares. The key strategies adopted by the major anesthesia equipment market players include product launches and approvals, acquisitions, partnerships, agreements, collaborations, and expansions.
Hologic (US) is a leading player in the global breast lesion localization market. The broad portfolio of breast lesion localization products is a major factor responsible for its large share in this market. The company focuses on both organic and inorganic growth strategies to enhance its footprint in the global market. Additionally, over the last few years, Hologic has strengthened its customer base and expanded its product portfolio through inorganic growth strategies, such as acquisitions and partnerships. With its strong product portfolio and wide geographic presence, Hologic is expected to witness significant growth in the breast lesion localization market during the forecast period.
To know about the assumptions considered for the study download the pdf brochure
Becton, Dickinson and Company (BD)(US) is the second leading player in the breast lesion localization market. Through its Medication Delivery Solutions segment, the company offers wire and radio-guided localization devices in the breast surgery market. The company has acquired a product line of localization wires and devices to enhance its presence in this market. The company now focuses upon R&D to introduce newer and technologically sound products in the breast lesion localization market. The company marks footprints in various countries across the globe.
Leica Biosystems Nussloch GmbH (Germany) is a provider of microscopy, camera, and software solutions for the imaging and analysis of macro, micro, and nanostructures. The company provides breast lesion localization products under the Diagnostics segment. The company’s R&D, manufacturing, sales, distribution, service, and administrative facilities are present in more than 60 countries. The company is a part of a bigger organization of Danaher Corporation. The company also acquired Devicor Medical Products (US), a company that specializes in breast biopsy procedure products. The company operates in the breast lesion localization market through its Devicor Medical Products subsidiary. The company is represented in over 100 countries and has manufacturing facilities in 8 countries, sales & service organizations in 27 countries, and a network of dealers spanning the globe.
Breast Lesion Localization Market By Type (Wire, Radioisotope (ROLL, RSL), Magnetic, Electromagnetic Localization), Usage (Breast Biopsy, Lumpectomy), End User (Hospitals, Diagnostic Imaging Centers, Ambulatory Surgical Centers) - Global Forecast to 2028
Mr. Aashish Mehra
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.SEND ME A FREE SAMPLE